




Trojan Capital Fund

www.taml.co.uk March 2014

The investment objective of the Trojan Capital Fund is to provide capital growth over the longer term. The policy is to invest substantially in global equities but the fund may also invest in collective investment schemes and money market instruments. Any comparisons against indices are for illustrative purposes only.



March Commentary

Your Fund returned +1.7% during the month compared to +0.7% for the MSCI World Index.

One of the strongest contributors to performance this month was the US bank Wells Fargo that was added to the Fund last year. Wells is the only 'full-service' bank that we own in the Fund and it earns its place by being an exceptional franchise, with a solid balance sheet, trading on a very reasonable valuation. A number of facts mark Wells out from international peers— it made money

throughout the financial crisis; the return on assets of 1.5% is amongst the best in the banking world and allows Wells to deliver mid teens returns on equity despite having much lower leverage than its global peers. Net interest margins have been impacted by very low interest rates, but are still healthy at 3.3%. The loan to deposit ratio is 80%, underpinned by Wells' large and growing share of deposits in the US, so Wells is not dependent on other banks to fund its business. This all translates into a very profitable business, with good efficiency ratios

and low levels of problematic loans. Wells is determined to increase the cash it returns to shareholders as demonstrated by the latest 17% increase in the dividend. Naturally, Wells Fargo's business is predicated on the health of the US economy, and a normalisation of interest rates would be helpful, but to paraphrase Warren Buffett (Wells Fargo's largest shareholder) we think its earnings are virtually certain to be materially higher in 5, 10 and 20 years from now.

% Fund

3.6

43.5

52.3

4.2

100.0

Top 10 Holdings

Sage

Total

Total Top 10


23 other holdings

Cash & equivalent

Total return %

Return vs volatility since launch

Standard deviation of monthly returns %



Roche Holdings	5.2
Novartis	5.0
Microsoft	5.0
Becton Dickinson	4.6
American Express	4.5
Medtronic	4.0
Ebay	3.9
Unilever	3.9
Nestlé	3.8

Source: Lipper Hindsight

Risk analysis	Fund	Index*
Total return	+80.1%	+59.4%
Max drawdown ¹	-30.3%	-33.2%
Best month	+7.0%	+10.2%
Worst month	-9.4%	-10.6%
Positive months	+61.5%	+61.5%

Fund Information

A copy of the latest Prospectus upon which you should base your investment is available from Capita Financial Managers, the Funds Authorised Corporate Director and Administrator (Authorised and Regulated by the Financial Conduct Authority) on 0845 608 0950

Structure Sub-fund Trojan Investment Funds UCITS		Management Fee 'O' (ordinary) shares: 1.00% 'S' (charity) shares: 0.75%			Dealing	
				1.00%	Daily at noon	
				0.75%	Tel: 0845 608 0950	
Investment Adviser		'l' (intermediary) shares:		1.50%	Registrar	
Troy Asset Management Ltd		Dilution Levy		0.50%	Capita Financial Administrators Ltd	
Brookfield House		Ongoing Charges	'O' shares:	1.13%	Auditor	
44 Davies Street			'I' shares:	1.61%	Ernst & Young LLP	
London W1K 5JA		Dividend Ex Dates			Depositary	
Tel: 020 7499 4030		1 Aug (interim), 1 Feb (final)			BNY Mellon Trust & Depositary (UK) Limited	
Fax: 020 7491 2445		Dividend Pay Dates			Bloomberg	
email: info@taml.co.uk		30 Sep (interim), 31 Mar (final)			TRJCAPA_LN (Acc), TRJCAPI_LN (Inc)	
Fund Manager	Gabrielle Boyle	Fund Yield (historic 'O' Inc shares)		1.4%	SEDOL	
Currency	urrency £ Sterling Authorised Corporate Director			B0ZJ5S4 (Acc) B0ZJ023 (Inc)		
Initial Fee Nil		Capita Financial Managers Ltd			Pricing	
Launch Date 6 March 2006		Tel: 0845 300 2110			Fund prices published daily in the FT	

The views expressed in this report are not intended as an offer or solicitation for the purchase or sale of any investment or financial instrument. The information contained in this document does not constitute investment advice and should not be used as the basis of any investment decision. References to specific securities are included for the purposes of illustration only and should not be construed as a recommendation to buy or sell these securities. Although Troy uses all reasonable skill and care in compiling this report and considers the information to be reliable, no warranty is given as to its accuracy or completeness. The opinions expressed accurately reflect the views of Troy at the date of this document and, whilst the opinions stated are honestly held, they are not guarantees and should not be relied upon and may be subject to change without notice. The investments discussed may fluctuate in value and investors may get back less than they invested. Past performance is not a guide to future performance and the investment approach and process described may not be suitable for all investors. Issued by Troy Asset Management Limited, Brookfield House, 44 Davies Street, London W1K 5JA (registered in England & Wales No. 3930846). Registered office: Hill House, 1 Little New Street, London EC4A 3TR. Authorised and Regulated by the Financial Conduct Authority (registration No: 195764).